Age-related differences in the pathogenesis of calcific aortic stenosis: The potential role of resistin

International Journal of Cardiology

Volumn 142, Issue 2, 2010, Pages 126-132

  Mohty, Dania ^a   Pibarot, Philippe ^a   Després, Jean Pierre ^a,b   Cartier, Amélie ^a,b   Arsenault, Benoit ^a,b   Picard, Frédéric ^a   Mathieu, Patrick ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Aging; Aortic stenosis; Resistin

Indexed keywords

CALCIUM; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LEPTIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; RESISTIN;

AGED; AORTA STENOSIS; AORTA VALVE; ARTERY CALCIFICATION; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; INFLAMMATION; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PRIORITY JOURNAL; RISK FACTOR;

AGED; AGED, 80 AND OVER; AGING; AORTIC VALVE; AORTIC VALVE STENOSIS; BIOLOGICAL MARKERS; CALCINOSIS; CARDIOMYOPATHIES; COHORT STUDIES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; RESISTIN; RISK FACTORS;

EID: 77953478183     PISSN: 01675273     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.12.068     Document Type: Article

References (32)

1. Rajamannan N.M., Gersh B., and Bonow R.O. Calcific aortic stenosis: from bench to the bedside-emerging clinical and cellular concepts. Heart 89 7 (2003) 801-805
2. Olsson M., Thyberg J., and Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 19 5 (1999) 1218-1222
3. Otto C.M., Kuusisto J., Reichenbach D.D., Gown A.M., and O'Brien K.D. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 90 2 (1994) 844-853
4. Rajamannan N.M., Subramaniam M., Caira F., Stock S.R., and Spelsberg T.C. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 112 9 Suppl (2005) I229-I234
5. Caira F.C., Stock S.R., Gleason T.G., et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 47 8 (2006) 1707-1712
6. Rossebo A.B., and Pedersen T.R. Hyperlipidaemia and aortic valve disease. Curr Opin Lipidol 15 4 (2004) 447-451
7. Stewart B.F., Siscovick D., Lind B.K., et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 29 3 (1997) 630-634
8. Lindroos M., Kupari M., Heikkila J., and Tilvis R. Prevalence of aortic valve abnormalities in the elderly: an echocardiographic study of a random population sample. J Am Coll Cardiol 21 5 (1993) 1220-1225
9. Lamarche B., Despres J.P., Moorjani S., Cantin B., Dagenais G.R., and Lupien P.J. Prevalence of dyslipidemic phenotypes in ischemic heart disease (prospective results from the Quebec Cardiovascular Study). Am J Cardiol 75 17 (1995) 1189-1195
10. Unger R.H. Lipotoxic diseases. Annu Rev Med 53 (2002) 319-336
11. Gabriely I., Ma X.H., Yang X.M., Rossetti L., and Barzilai N. Leptin resistance during aging is independent of fat mass. Diabetes 51 4 (2002) 1016-1021
12. Slawik M., and Vidal-Puig A.J. Lipotoxicity, overnutrition and energy metabolism in aging. Ageing Res Rev 5 2 (2006) 144-164
13. Jung H.S., Park K.H., Cho Y.M., et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69 1 (2006) 76-85
14. Steppan C.M., and Lazar M.A. The current biology of resistin. J Intern Med 255 4 (2004) 439-447
15. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 7 (2005) 932-939
16. An P., Rice T., Gagnon J., et al. Segregation analysis of apolipoproteins A-1 and B-100 measured before and after an exercise training program: the HERITAGE Family Study. Arterioscler Thromb Vasc Biol 20 3 (2000) 807-814
17. O'Brien K.D. Pathogenesis of calcific aortic valve disease: a disease process comes of age (and a good deal more). Arterioscler Thromb Vasc Biol 26 8 (2006) 1721-1728
18. Charest A., Pepin A., Shetty R., et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 92 12 (2006) 1844-1849
19. Mohty D., Pibarot P., Despres J.P., et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 28 1 (2008) 187-193
20. Pascot A., Lemieux I., Prud'homme D., et al. Reduced HDL particle size as an additional feature of the atherogenic dyslipidemia of abdominal obesity. J Lipid Res 42 12 (2001) 2007-2014
21. Walldius G., and Jungner I. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy - a review of the evidence. J Intern Med 259 5 (2006) 493-519
22. Barzilai N., Atzmon G., Schechter C., et al. Unique lipoprotein phenotype and genotype associated with exceptional longevity. JAMA 290 15 (2003) 2030-2040
23. Verma S., Li S.H., Wang C.H., et al. Resistin promotes endothelial cell activation: further evidence of adipokine-endothelial interaction. Circulation 108 6 (2003) 736-740
24. Tintut Y., Patel J., Territo M., Saini T., Parhami F., and Demer L.L. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 105 5 (2002) 650-655
25. O'Brien K.D., Reichenbach D.D., Marcovina S.M., Kuusisto J., Alpers C.E., and Otto C.M. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 16 4 (1996) 523-532
26. Lin S.L., Liu C.P., Young S.T., Lin M., and Chiou C.W. Age-related changes in aortic valve with emphasis on the relation between pressure loading and thickened leaflets of the aortic valves. Int J Cardiol 103 3 (2005) 272-279
27. Orlandi A., Marcellini M., and Spagnoli L.G. Aging influences development and progression of early aortic atherosclerotic lesions in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 20 4 (2000) 1123-1136
28. Cowell S.J., Newby D.E., Prescott R.J., et al. A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. N Engl J Med 352 23 (2005) 2389-2397
29. Moura L.M., Ramos S.F., Zamorano J.L., et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 49 5 (2007) 554-561
30. Patel L., Buckels A.C., Kinghorn I.J., et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300 2 (2003) 472-476
31. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366 9493 (2005) 1279-1289
32. Coats A.J. Ethical authorship and publishing. Int J Cardiol 131 (2009) 149-150